A single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients

There are few studies that compare the safety of multiple induction therapies in simultaneous pancreas-kidney transplant (SPKT) patients. The purpose of this study is to compare basiliximab, thymoglobulin (ATG), and alemtuzumab according to HLA matching to assess allograft survival, rejection rate, and post-operative complications.